This page shows the latest Affimed news and features for those working in and with pharma, biotech and healthcare.
In this case however the concerns were about liver toxicity. A few weeks earlier a trial of Affimed’s CD3- and CD19-targeting bispecific AFM11 in non-Hodgkin’s lymphoma was
German biotech Affimed saw its share price more than triple yesterday after Roche’s Genentech agreed an alliance to discover new cancer immunotherapies with a jaw-dropping milestone figure. ... Roche is paying $96m in upfront and near-term funding
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....